pyrazolam pyrazolam pyrazolam (sh-i-04) is a benzodiazepine derivative originally developed by a team led by leo sternbach at hoffman-la roche in the 1970s. it has since been "rediscovered" and sold as a designer drug since 2012. pyrazolamclinical dataroutes ofadministrationoral, sublingual, rectallegal statuslegal status au: s4 ca: schedule iv de: npsg (industrial and scientific use only) uk: class c us: unscheduled pharmacokinetic dataelimination half-life17 hoursidentifiers iupac name 8-bromo-1-methyl-6-(pyridin-2-yl)-4h-triazolobenzodiazepine cas number39243-02-2pubchem cid12562545chemspider15417688unii8lh16383pkchemblchembl3246831chemical and physical dataformulac16h12brn5molar mass354.211 g·mol−13d model (jsmol)interactive image smiles cc1=nn=c2cn=c(c3=nc=cc=c3)c3=cc(br)=cc=c3n12 inchi inchi=1s/c16h12brn5/c1-10-20-21-15-9-19-16(13-4-2-3-7-18-13)12-8-11(17)5-6-14(12)22(10)15/h2-8h,9h2,1h3key:bgrwsfiqqpveml-uhfffaoysa-n pyrazolam has structural similarities to alprazolam and bromazepam. unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine. it is most selective for the α2 and α3 subtypes of the gabaa receptor. legal status united kingdom in the uk, pyrazolam has been classified as a class c drug by section 5 of the may 2017 amendment to the misuse of drugs act 1971 along with several other designer benzodiazepine drugs.